Ischemic nephropathy/azotemic renovascular disease

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Vascular Surgery

Background:

• Atherosclerotic renal vascular disease compromises kidney perfusion, potentially leading to irreversible kidney damage.
• The exact mechanisms transforming reversible injury into irreversible damage are unclear, but inflammation and fibrosis pathways are implicated.
• This condition is a significant contributor to end-stage renal disease, affecting 12-18% of patients in Western countries.

Purpose of the Study:

• To highlight the importance of identifying atherosclerotic renal vascular disease.
• To discuss the risks associated with antihypertensive therapy in these patients.
• To explore the benefits and risks of revascularization procedures.

Main Methods:

• Review of existing literature on atherosclerotic renal vascular disease.
• Analysis of clinical outcomes following antihypertensive therapy and revascularization.
• Identification of factors contributing to kidney function loss post-revascularization.

Main Results:

• Antihypertensive medications, including ACE inhibitors, can reduce glomerular filtration rate (GFR) in patients with renal artery stenosis.
• Renal revascularization can prevent disease progression and sometimes improve kidney function.
• Some patients experience further kidney function decline after revascularization due to factors like atheroemboli.

Conclusions:

• Careful patient selection for renal revascularization is essential, balancing comorbid risks against potential benefits.
• Further research is needed to identify individuals at high risk for irreversible kidney function loss who would benefit most from vascular repair.